Literature DB >> 11511096

SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus.

I Imoto1, A Pimkhaokham, Y Fukuda, Z Q Yang, Y Shimada, N Nomura, H Hirai, M Imamura, J Inazawa.   

Abstract

Amplification of the 3q26 region appears to occur frequently among esophageal squamous cell carcinomas (ESCs). We examined ESC cell lines for amplification and expression levels of four genes in this region: SNO and EVI1, which encode proteins antagonizing transforming growth factor-beta signaling, and two other putative target genes, TERC and PIK3CA. Amplification of SNO was accompanied by significant increases in its expression level, suggesting that this gene is activated in an amplification-dependent manner. SNO was also amplified in 5 of 44 primary ESCs (11.4%). However, expression levels of EVI1, TERC, and PIK3CA did not correlate with their copy-numbers, even though EVI1 and TERC showed the same amplification pattern as SNO. Taken together, the data suggest that of the four candidates, SNO is the most probable target in the 3q26 amplicon for involvement in the progression of ESC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511096     DOI: 10.1006/bbrc.2001.5428

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

1.  Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins.

Authors:  Ariel R Krakowski; Julien Laboureau; Alain Mauviel; Mina J Bissell; Kunxin Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

2.  Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells.

Authors:  Suman Sengupta; Samir Jana; Subir Biswas; Palash Kumar Mandal; Arindam Bhattacharyya
Journal:  Clin Exp Metastasis       Date:  2013-07-06       Impact factor: 5.150

3.  The chromosome 3q26 OncCassette: A multigenic driver of human cancer.

Authors:  Alan P Fields; Verline Justilien; Nicole R Murray
Journal:  Adv Biol Regul       Date:  2015-12-23

4.  Phosphorylation of the anaphase-promoting complex/Cdc27 is involved in TGF-beta signaling.

Authors:  Liyong Zhang; Takeo Fujita; George Wu; Xiao Xiao; Yong Wan
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 5.  Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.

Authors:  Alan P Fields; Roderick P Regala
Journal:  Pharmacol Res       Date:  2007-05-05       Impact factor: 7.658

6.  The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.

Authors:  Verline Justilien; Michael P Walsh; Syed A Ali; E Aubrey Thompson; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  Dual role of SnoN in mammalian tumorigenesis.

Authors:  Qingwei Zhu; Ariel R Krakowski; Elizabeth E Dunham; Long Wang; Abhik Bandyopadhyay; Rebecca Berdeaux; G Steven Martin; LuZhe Sun; Kunxin Luo
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

8.  Differential role of Sloan-Kettering Institute (Ski) protein in Nodal and transforming growth factor-beta (TGF-β)-induced Smad signaling in prostate cancer cells.

Authors:  BaoHan T Vo; Bianca Cody; Yang Cao; Shafiq A Khan
Journal:  Carcinogenesis       Date:  2012-07-27       Impact factor: 4.944

9.  Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.

Authors:  Meera Nanjundan; Kwai Wa Cheng; Fan Zhang; John Lahad; Wen-Lin Kuo; Rosemarie Schmandt; Karen Smith-McCune; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

10.  Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma.

Authors:  Thomas Longerich; Kai Breuhahn; Margarete Odenthal; Katharina Petmecky; Peter Schirmacher
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.